share_log

Oppenheimer Maintains Outperform on Chemomab Therapeutics, Lowers Price Target to $7

Oppenheimer Maintains Outperform on Chemomab Therapeutics, Lowers Price Target to $7

奥本海默维持Chemomab Therapeutics的跑赢大盘,将目标股价下调至7美元
Benzinga ·  2023/04/18 07:12

Oppenheimer analyst Jeff Jones maintains Chemomab Therapeutics (NASDAQ:CMMB) with a Outperform and lowers the price target from $12 to $7.

奥本海默分析师杰夫·琼斯维持Chemomab Therapeutics(纳斯达克股票代码:CMMB)的表现跑赢大盘,并将目标股价从12美元下调至7美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发